Innovationews - "Biodesix Inc. announced new clinical findings that show its novel investigational test, BDX008 – based on profiling serum proteins – identifies patients with advanced melanoma who are more likely to have longer progression-free and overall survival with nivolumb therapy." Read the full story.
Topics: melanoma, nivolumab, immunotherapy test, In the News, innovationews story, nivolumab test, clinical findings immunotherapy